表紙
市場調查報告書

生物醫藥品的全球市場 - 各類型、用途、地區 - 成長,趨勢,及預測(2018年∼2023年)

Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390811
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
生物醫藥品的全球市場 - 各類型、用途、地區 - 成長,趨勢,及預測(2018年∼2023年) Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 114 Pages
簡介

全球生物醫藥品市場,預計從2018年到2023年,以8.5%的年複合成長率擴大,2023年達到3,411億6,000萬美元。

本報告提供生物醫藥品的全球市場調查,市場概要,各類型、治療用途、地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析

  • 市場成長要素
  • 市場阻礙因素
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品類型
    • 單株抗體
    • 組換成長因素
    • 煉製蛋白質
    • 重組蛋白質
    • 重組荷爾蒙
    • 合成免疫調節劑
    • 疫苗
  • 各治療用途
    • 腫瘤
    • 發炎性感染疾病
    • 自體免疫疾病
    • 代謝性疾病
    • 荷爾蒙疾病
    • 疾病預防
    • 心血管疾病
    • 神經疾病
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲

第8章 競爭情形

  • M&A分析
  • 協定,聯盟,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co.
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Roche Holding AG
  • Others

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51323

Market Overview

The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.

Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.

Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.

Scope of the Report

For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.

Key Market Trends

Monoclonal Antibodies are Expected to have the Largest Market Size

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.

North America is Expected to Dominate the Biopharmaceuticals Market

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Acceptance for Biopharmaceuticals
    • 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
    • 4.2.3 Huge Market Demand
  • 4.3 Market Restraints
    • 4.3.1 Increasing Demand for Affordable Biopharmaceuticals
    • 4.3.2 High-end Manufacturing Requirements
    • 4.3.3 Complicated and Cumbersome Regulatory Requirements

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Monoclonal Antibodies
      • 5.1.1.1 Anti Cancer Monoclonal Antibodies
      • 5.1.1.2 Anti-inflammatory Monoclonal Antibodies
      • 5.1.1.3 Other Monoclonal Antibodies
    • 5.1.2 Recombinant Growth Factors
      • 5.1.2.1 Erythropoietin
      • 5.1.2.2 Granulocyte Colony Stimulating Factor
    • 5.1.3 Purified Proteins
      • 5.1.3.1 Leukemia Inhibitory Factor (LIF)
      • 5.1.3.2 P53 Protein
      • 5.1.3.3 P38 Protein
      • 5.1.3.4 Other Purified Proteins
    • 5.1.4 Recombinant Proteins
      • 5.1.4.1 Serum Albumin
      • 5.1.4.2 Amyloid Protein
      • 5.1.4.3 Defensin
      • 5.1.4.4 Transferrin
    • 5.1.5 Recombinant Hormones
      • 5.1.5.1 Recombinant Hormones
      • 5.1.5.2 Recombinant Insulin
      • 5.1.5.3 Other Recombinant Hormones
    • 5.1.6 Vaccines
      • 5.1.6.1 Recombinant Vaccines
      • 5.1.6.1.1 Cancer Vaccines
      • 5.1.6.1.2 Malaria Vaccines
      • 5.1.6.1.3 Ebola Vaccine
      • 5.1.6.1.4 Hepatitis-b Vaccine
      • 5.1.6.1.5 Tetanus Vaccine
      • 5.1.6.1.6 Diptheria Vaccine
      • 5.1.6.1.7 Cholera Vaccine
      • 5.1.6.1.8 Other Vaccines
      • 5.1.6.2 Conventional Vaccines
      • 5.1.6.2.1 Polio Vaccine
      • 5.1.6.2.2 Pox Vaccine
      • 5.1.6.2.3 Other Conventional Vaccines
      • 5.1.6.3 Recombinant Enzymes
      • 5.1.6.3.1 Enterokinase
      • 5.1.6.3.2 Cyclase
      • 5.1.6.3.3 Caspase
      • 5.1.6.3.4 Cathepsin
      • 5.1.6.4 Cell and Gene Therapies
      • 5.1.6.4.1 Allogeneic Products
      • 5.1.6.4.2 Autologous Products
      • 5.1.6.4.3 Acellular Products
      • 5.1.6.5 Other Product Types
      • 5.1.6.5.1 Blood Factors
      • 5.1.6.5.2 Other Product Types
    • 5.1.7 Synthetic Immunomodulators
      • 5.1.7.1 Cytokines, Interferones, Interleukins
      • 5.1.7.2 Tumor Necrosis Factor (TNF)
  • 5.2 By Therapeutic Application
    • 5.2.1 Oncology
    • 5.2.2 Inflammatory and Infectious Diseases
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Metabolic Disorders
    • 5.2.5 Hormonal Disorders
    • 5.2.6 Disease Prevention
    • 5.2.7 Cardiovascular Diseases
    • 5.2.8 Neurological Diseases
    • 5.2.9 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 India
      • 5.3.3.2 China
      • 5.3.3.3 Japan
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Eli Lily & Co.
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Novo Nordisk Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 Roche Holding AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS